Dont miss SGLT Tools - PowerPoint slide library for SGLT2 inhibitors

General Nephrology

General Nephrology

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

ernando C. Fervenza, M.D., Ph.D., Gerald B. Appel, M.D., Sean J. Barbour, M.D., Brad H. Rovin, M.D., Richard A. Lafayette, M.D., Nabeel Aslam, M.D., Jonathan A. Jefferson, M.D., Patrick E. Gipson, M.D., Dana V. Rizk, M.D., John R. Sedor, M.D., James F. Si
https://www.ncbi.nlm.nih.gov/pubmed/31269364
Google Plus
LinkedIn

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic, M.B., B.S., Ph.D., Meg J. Jardine, M.B., B.S., Ph.D., Bruce Neal, M.B., Ch.B., Ph.D., Severine Bompoint, B.Sc., Hiddo J.L. Heerspink, Pharm.D., Ph.D., David M. Charytan, M.D., Robert Edwards, M.P.H., Rajiv Agarwal, M.D., George Bakris, M.D
Google Plus
LinkedIn

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, M.D., Itamar Raz, M.D., Marc P. Bonaca, M.D., M.P.H., Ofri Mosenzon, M.D., Eri T. Kato, M.D., M.P.H., Ph.D., Avivit Cahn, M.D., Michael G. Silverman, M.D., M.P.H., Thomas A. Zelniker, M.D., Julia F. Kuder, M.A., Sabina A. Murphy, M.P.H
Google Plus
LinkedIn

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.
N Engl J Med. 2017 Nov 4
Google Plus
LinkedIn

Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine

Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM; PRESERVE Trial Group
N Engl J Med. 2017 Nov 12. doi: 10.1056/NEJMoa1710933
Google Plus
LinkedIn

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920
Google Plus
LinkedIn

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications

Hiddo J.L. Heerspink, Bruce A. Perkins, David H. Fitchett, Mansoor Husain, David Z. I. Cherney
Circulation. 2016 Sep 6;134(10):752-72
Google Plus
LinkedIn

Intensive Supportive Care plus Immunosuppression in IgA Nephropathy

Ayoub I, Hebert L Rovin BH
N Engl J Med. 2015 Dec 3;373(23):2225-36
Google Plus
LinkedIn

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, R
N Engl J Med. 2014 Nov 6;371(19):1771-80
Google Plus
LinkedIn

Efficacy of remission-induction regimens for ANCA-associated vasculitis

Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH; RAVE-ITN Research Group.
N Engl J Med. 2013 Aug 1;369(5):417-27
Google Plus
LinkedIn

IgA nephropathy

Wyatt RJ, Julian BA
N Engl J Med. 2013 Jun 20;368(25):2402-14
Google Plus
LinkedIn

[12 3 4  >>  
ukidneyisup